106 related articles for article (PubMed ID: 38747491)
21. Improving Ki67 assessment concordance by the use of an artificial intelligence-empowered microscope: a multi-institutional ring study.
Cai L; Yan K; Bu H; Yue M; Dong P; Wang X; Li L; Tian K; Shen H; Zhang J; Shang J; Niu S; Han D; Ren C; Huang J; Han X; Yao J; Liu Y
Histopathology; 2021 Oct; 79(4):544-555. PubMed ID: 33840132
[TBL] [Abstract][Full Text] [Related]
22. Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study.
Yue M; Zhang J; Wang X; Yan K; Cai L; Tian K; Niu S; Han X; Yu Y; Huang J; Han D; Yao J; Liu Y
Virchows Arch; 2021 Sep; 479(3):443-449. PubMed ID: 34279719
[TBL] [Abstract][Full Text] [Related]
23. The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer.
Wu S; Yue M; Zhang J; Li X; Li Z; Zhang H; Wang X; Han X; Cai L; Shang J; Jia Z; Wang X; Li J; Liu Y
Mod Pathol; 2023 Mar; 36(3):100054. PubMed ID: 36788100
[TBL] [Abstract][Full Text] [Related]
24. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
[TBL] [Abstract][Full Text] [Related]
25. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
[No Abstract] [Full Text] [Related]
26. Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images.
Vahadane A; Sharma S; Mandal D; Dabbeeru M; Jakthong J; Garcia-Guzman M; Majumdar S; Lee CW
Comput Biol Med; 2023 Jan; 152():106337. PubMed ID: 36502695
[TBL] [Abstract][Full Text] [Related]
27. Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores.
Lea D; Zaharia C; Søreide K
Cancer Treat Res Commun; 2024; 38():100788. PubMed ID: 38150845
[TBL] [Abstract][Full Text] [Related]
28. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
29. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
Wang X; He J; Li J; Wu C; Yue M; Niu S; Jia Y; Jia Z; Cai L; Liu Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):43. PubMed ID: 38280970
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer.
Hondelink LM; Hüyük M; Postmus PE; Smit VTHBM; Blom S; von der Thüsen JH; Cohen D
Histopathology; 2022 Mar; 80(4):635-647. PubMed ID: 34786761
[TBL] [Abstract][Full Text] [Related]
31. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
Cortes J; Winer EP; Lipatov O; Im SA; Gonçalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Hund S; Kulangara K; Karantza V; Mejia JA; Ma J; Jelinic P; Huang L; Pruitt SK; Emancipator K
J Pathol Clin Res; 2024 May; 10(3):e12371. PubMed ID: 38627977
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
[TBL] [Abstract][Full Text] [Related]
33. Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis.
Darmon-Novello M; Adam J; Lamant L; Battistella M; Ortonne N; Balme B; de la Fouchardière A; Chaltiel L; Gerard E; Franchet C; Vergier B
Histopathology; 2022 Jun; 80(7):1091-1101. PubMed ID: 35322452
[TBL] [Abstract][Full Text] [Related]
34. Development and Validation of an Artificial Intelligence-Powered Platform for Prostate Cancer Grading and Quantification.
Huang W; Randhawa R; Jain P; Iczkowski KA; Hu R; Hubbard S; Eickhoff J; Basu H; Roy R
JAMA Netw Open; 2021 Nov; 4(11):e2132554. PubMed ID: 34730818
[TBL] [Abstract][Full Text] [Related]
35. Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists.
Ahn S; Kwak Y; Kwon GY; Kim KM; Kim M; Kim H; Park YS; Oh HJ; Lee K; Lee SH; Lee HS
J Pathol Transl Med; 2024 May; 58(3):103-116. PubMed ID: 38653580
[TBL] [Abstract][Full Text] [Related]
36. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
[TBL] [Abstract][Full Text] [Related]
37. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
[TBL] [Abstract][Full Text] [Related]
38. Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.
Fernandez AI; Robbins CJ; Gaule P; Agostini-Vulaj D; Anders RA; Bellizzi AM; Chen W; Chen ZE; Gopal P; Zhao L; Lisovsky M; Liu X; Shia J; Wang H; Yang Z; McCann L; Chan YG; Weidler J; Bates M; Zhang X; Rimm DL
Mod Pathol; 2023 May; 36(5):100128. PubMed ID: 36889057
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer.
Choi H; Ahn SG; Bae SJ; Kim JH; Eun NL; Lee Y; Nahm JH; Jeong J; Cha YJ
Yonsei Med J; 2023 Aug; 64(8):518-525. PubMed ID: 37488704
[TBL] [Abstract][Full Text] [Related]
40. Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging.
Hoda RS; Brogi E; D'Alfonso TM; Grabenstetter A; Giri D; Hanna MG; Kuba MG; Murray MP; Vallejo CE; Zhang H; Reis-Filho JS; Wen HY
Arch Pathol Lab Med; 2021 Sep; 145(9):1132-1137. PubMed ID: 33417715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
